Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Value of Renal Vascular Doppler Sonography in Management of Decompensated Heart Failure

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02372292
Recruitment Status : Completed
First Posted : February 26, 2015
Last Update Posted : June 23, 2015
Sponsor:
Information provided by (Responsible Party):
Özgür Ulaş Özcan, Ankara University

Brief Summary:
Although the traditional determinant of renal dysfunction in heart failure was suggested as decreased cardiac output and renal hypo perfusion, recent studies have demonstrated the association of persistent systemic venous congestion and kidney dysfunction. Relief of the congestion has demonstrated to improve renal functions in decompensated heart failure. The current trial was set up to investigate the changes of renal venous impedance and renal arteriolar resistivity indices with diuretic therapy, in patients with congestive renal failure. The investigators asked whether measurement of renal venous impedance index or renal arteriolar resistivity index can guide the practice of diuretic therapy.

Condition or disease Intervention/treatment Phase
Cardiorenal Syndrome Drug: intravenous furosemide Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Diagnostic
Official Title: Value of Renal Vascular Doppler Sonography in Management of Decompensated Heart Failure
Study Start Date : February 2013
Actual Primary Completion Date : June 2015
Actual Study Completion Date : June 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure
Drug Information available for: Furosemide

Arm Intervention/treatment
Active Comparator: Group 1
Patients with type 1 cardiorenal syndrome who had improvement of renal functions along with diuretic therapy. Intravenous furosemide treatment.
Drug: intravenous furosemide
Decongestant therapy for decompensated heart failure which may be administrated as intravenous bolus or infusion
Other Name: Lasix

Active Comparator: Group 2
Patients with type 1 cardiorenal syndrome who did not have improvement of renal functions along with diuretic therapy. Intravenous furosemide treatment.
Drug: intravenous furosemide
Decongestant therapy for decompensated heart failure which may be administrated as intravenous bolus or infusion
Other Name: Lasix




Primary Outcome Measures :
  1. Alterations in the renal arterial resistivity index [ Time Frame: during hospitalization, an expected average of 4 weeks. ]
    Participants will be followed for the duration of hospital stay, an expected average of 4 weeks.


Secondary Outcome Measures :
  1. Alterations in the renal venous impedance index [ Time Frame: during hospitalization, an expected average of 4 weeks. ]
    Participants will be followed for the duration of hospital stay, an expected average of 4 weeks.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Decompensated heart failure
  • Elevated serum creatinine levels on admission

Exclusion Criteria:

  • Atrial fibrillation
  • Obstructive uropathy
  • Patients with ascites
  • Patients who exposed the potential nephrotoxic drugs in the previous week (metformin, antibiotics, chemotherapeutics, iodinated contrast agents and non-steroidal anti-inflammatory agents)
  • Patients who needed positive inotropic agents

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02372292


Locations
Layout table for location information
Turkey
Ankara University School Of Medicine, Department of Cardiology
Ankara, Turkey, 06230
Sponsors and Collaborators
Ankara University

Layout table for additonal information
Responsible Party: Özgür Ulaş Özcan, MD, Ankara University
ClinicalTrials.gov Identifier: NCT02372292     History of Changes
Other Study ID Numbers: Ankararenal
First Posted: February 26, 2015    Key Record Dates
Last Update Posted: June 23, 2015
Last Verified: June 2015
Keywords provided by Özgür Ulaş Özcan, Ankara University:
cardiorenal syndrome, decompensated heart failure, renal resistivity index, venous impedance index, kidney failure
Additional relevant MeSH terms:
Layout table for MeSH terms
Furosemide
Cardio-Renal Syndrome
Heart Failure
Heart Diseases
Cardiovascular Diseases
Renal Insufficiency
Kidney Diseases
Urologic Diseases
Diuretics
Natriuretic Agents
Physiological Effects of Drugs
Sodium Potassium Chloride Symporter Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action